Factors associated with HPV vaccine hesitancy: A nationally representative cross-sectional study

IF 4.5 3区 医学 Q2 IMMUNOLOGY
Lygia Maria Costa Soares , Ana Elza Oliveira de Medonça , Dyego Leandro Bezerra de Souza , Ariane Vieira Carvalho , Matheus Gonçalves Flores , Avelar Macedo Neto , Diocésio Alves Pinto de Andrade , Angélica Nogueira Rodrigues
{"title":"Factors associated with HPV vaccine hesitancy: A nationally representative cross-sectional study","authors":"Lygia Maria Costa Soares ,&nbsp;Ana Elza Oliveira de Medonça ,&nbsp;Dyego Leandro Bezerra de Souza ,&nbsp;Ariane Vieira Carvalho ,&nbsp;Matheus Gonçalves Flores ,&nbsp;Avelar Macedo Neto ,&nbsp;Diocésio Alves Pinto de Andrade ,&nbsp;Angélica Nogueira Rodrigues","doi":"10.1016/j.vaccine.2025.127278","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>HPV related tumors continue to be a global leading cause of cancer mainly due to cervical cancer (CC) burden. In Brazil, CC is the third most common cancer and the fourth highest cancer mortality rate among women. HPV vaccine mass immunization represents the current most promising intervention for CC prevention. It was first implemented in the Brazilian public health system in 2014, however, despite a history of excellent coverage for other vaccines, HPV vaccine uptake is below the necessary threshold for CC elimination. Identifying the factors that influence HPV vaccine hesitancy is an essential step to further develop strategies to improve vaccination coverage.</div></div><div><h3>Objectives</h3><div>The aim of this study is to provide insights into whether or not Brazilians are resistant to HPV vaccination and to determine the factors and variables that influence this decision.</div></div><div><h3>Methods</h3><div>This is a population-based cross-sectional study which used quantitative methodology through personal interviews. A total of 2010 interviews were planned to result in error margins of 2 percentage points, more or less considering a 95 % confidence level, encompassing all five Brazilian regions. Cities of different sizes and complexities were included in the sample, as capitals and cities in both metropolitan and rural areas. The research was carried out with the Brazilian population aged 16 and over, interviewees were approached at points of population flow.</div></div><div><h3>Results</h3><div>Between June 12th and 16th 2023, a total of 2010 personal interviews were done, with participants from all five Brazilian regions. The prevalence of vaccine resistance was 5.97 % (95 % confidence interval [CI], 4.93–7.23) among those interviewed. A multivariate analysis demonstrated greater resistance to the vaccine among men (prevalence ratios (PR): 1.58; 95 %CI 1.06–2.34; <em>p:</em> 0.023) and residents in the South region of the country (PR: 1.77; 95 %CI, 1.06–2.94; <em>p:</em> 0.028). The three main reasons for refusing the vaccine reported by the participants were: lack of knowledge about the HPV vaccine; difficulty in accessing the vaccine; and lack of vaccine prescription by health professionals. Safety was the main reason not to vaccinate, cited by 10 %.</div></div><div><h3>Conclusions</h3><div>Despite HPV vaccine availability in Brazil at the public health system, vaccination coverage remains below the target for both genders. However, according to this analysis, there is a low rate of HPV vaccination hesitancy in the country, being lack of knowledge, difficulty in accessing the vaccine and lack of vaccine prescription by health professionals the main obstacles to adequate adherence. The COVID-19 pandemic doesn't seem to have affected HPV vaccination resistance in the country. Proper strategies for vaccine implementation, including school-based programs, patient-provider communication and education, and integrated monitoring and evaluation strategies are needed, otherwise HPV vaccine programs run the risk of repeating the problems associated with Pap programs in Low- and Middle-Income Countries (LMICs): an efficient, life-saving tool underutilized for cancer prevention.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"59 ","pages":"Article 127278"},"PeriodicalIF":4.5000,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X25005754","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

HPV related tumors continue to be a global leading cause of cancer mainly due to cervical cancer (CC) burden. In Brazil, CC is the third most common cancer and the fourth highest cancer mortality rate among women. HPV vaccine mass immunization represents the current most promising intervention for CC prevention. It was first implemented in the Brazilian public health system in 2014, however, despite a history of excellent coverage for other vaccines, HPV vaccine uptake is below the necessary threshold for CC elimination. Identifying the factors that influence HPV vaccine hesitancy is an essential step to further develop strategies to improve vaccination coverage.

Objectives

The aim of this study is to provide insights into whether or not Brazilians are resistant to HPV vaccination and to determine the factors and variables that influence this decision.

Methods

This is a population-based cross-sectional study which used quantitative methodology through personal interviews. A total of 2010 interviews were planned to result in error margins of 2 percentage points, more or less considering a 95 % confidence level, encompassing all five Brazilian regions. Cities of different sizes and complexities were included in the sample, as capitals and cities in both metropolitan and rural areas. The research was carried out with the Brazilian population aged 16 and over, interviewees were approached at points of population flow.

Results

Between June 12th and 16th 2023, a total of 2010 personal interviews were done, with participants from all five Brazilian regions. The prevalence of vaccine resistance was 5.97 % (95 % confidence interval [CI], 4.93–7.23) among those interviewed. A multivariate analysis demonstrated greater resistance to the vaccine among men (prevalence ratios (PR): 1.58; 95 %CI 1.06–2.34; p: 0.023) and residents in the South region of the country (PR: 1.77; 95 %CI, 1.06–2.94; p: 0.028). The three main reasons for refusing the vaccine reported by the participants were: lack of knowledge about the HPV vaccine; difficulty in accessing the vaccine; and lack of vaccine prescription by health professionals. Safety was the main reason not to vaccinate, cited by 10 %.

Conclusions

Despite HPV vaccine availability in Brazil at the public health system, vaccination coverage remains below the target for both genders. However, according to this analysis, there is a low rate of HPV vaccination hesitancy in the country, being lack of knowledge, difficulty in accessing the vaccine and lack of vaccine prescription by health professionals the main obstacles to adequate adherence. The COVID-19 pandemic doesn't seem to have affected HPV vaccination resistance in the country. Proper strategies for vaccine implementation, including school-based programs, patient-provider communication and education, and integrated monitoring and evaluation strategies are needed, otherwise HPV vaccine programs run the risk of repeating the problems associated with Pap programs in Low- and Middle-Income Countries (LMICs): an efficient, life-saving tool underutilized for cancer prevention.
HPV疫苗犹豫相关因素:一项具有全国代表性的横断面研究
dhpv相关肿瘤仍然是全球癌症的主要原因,主要是由于宫颈癌(CC)负担。在巴西,CC是妇女中第三常见的癌症,也是死亡率第四大的癌症。HPV疫苗大规模免疫是目前预防CC最有希望的干预措施。该疫苗于2014年首次在巴西公共卫生系统实施,然而,尽管其他疫苗的覆盖率很高,但HPV疫苗的吸收率低于消除CC的必要阈值。确定影响人乳头瘤病毒疫苗犹豫的因素是进一步制定提高疫苗接种覆盖率战略的重要步骤。本研究的目的是深入了解巴西人是否对HPV疫苗有抵抗力,并确定影响这一决定的因素和变量。方法这是一项基于人群的横断面研究,通过个人访谈采用定量方法。总共进行了2010次访谈,考虑到95%的置信度,误差幅度在2个百分点左右,涵盖了巴西所有五个地区。样本中包括不同规模和复杂程度的城市,如首都和大都市和农村地区的城市。这项研究是在巴西16岁及以上的人口中进行的,受访者在人口流动的时候接触。结果:在2023年6月12日至16日期间,共进行了2010次个人访谈,参与者来自巴西所有五个地区。受访人群的疫苗耐药率为5.97%(95%可信区间[CI], 4.93 ~ 7.23)。一项多变量分析显示,男性对疫苗的抵抗力更强(患病率比(PR): 1.58;95% ci 1.06-2.34;p: 0.023)和该国南部地区的居民(PR: 1.77;95% ci, 1.06-2.94;p: 0.028)。参与者报告的拒绝接种疫苗的三个主要原因是:缺乏对HPV疫苗的了解;难以获得疫苗;缺乏卫生专业人员开具的疫苗处方。10%的人认为安全是不接种疫苗的主要原因。结论:尽管巴西公共卫生系统提供了HPV疫苗,但疫苗接种覆盖率仍低于男女目标。然而,根据这一分析,该国人乳头瘤病毒疫苗接种的犹豫率很低,缺乏知识、难以获得疫苗和缺乏卫生专业人员的疫苗处方是充分坚持接种的主要障碍。COVID-19大流行似乎并未影响该国的HPV疫苗耐药性。需要适当的疫苗实施策略,包括以学校为基础的计划,患者与提供者的沟通和教育,以及综合监测和评估策略,否则HPV疫苗计划有重复低收入和中等收入国家(LMICs) Pap计划相关问题的风险:一种有效的,挽救生命的工具,未被充分利用用于癌症预防。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Vaccine
Vaccine 医学-免疫学
CiteScore
8.70
自引率
5.50%
发文量
992
审稿时长
131 days
期刊介绍: Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信